Patent ID: 8580292

Claim:
A method for treating an ocular condition in a patient in need thereof, comprising the step of placing a biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix into the vitreous of an eye of the patient, wherein a therapeutically effective amount of the alpha-2 adrenergic receptor agonist associated with the biodegradable polymer matrix is released into the eye for a time period greater than about one month from the time the biodegradable intraocular implant is placed in the eye, wherein the ocular condition is selected from the group consisting of Cystoid Macular Edema, Diabetic Macular Edema, and Retinal Detachment, and wherein the biodegradable polymer matrix comprises a mixture of first and second biodegradable polymers, wherein the first biodegradable polymer is a polylactide having a molecular weight of about 63.3 kD, and the second biodegradable polymer is a polylactide having a molecular weight of about 14 kD.